Advertisement

Na+/I Symporter Target for Thyroid Disease Imaging and Treatment

  • Rui HuangEmail author
  • Rong Tian
  • Zhaowei Meng
Chapter

Abstract

Utilizing iodide to synthesize thyroid hormones is a biological signature of thyroid that has been used for the diagnosis and treatment of benign and malignant thyroid diseases [1]. Radioiodine is a classical theranostic representations for personalized targeted therapy and molecular imaging in nuclear medicine history [2]. Thyroid scan with radioiodine or technetium-99m (99mTc) pertechnetate has unique ability in the assessment of thyroid nodules with anatomical and functional information. Radioiodine whole-body scan (WBS) has played an important role in the detection of normal thyroid tissue remnants and local and distant metastases of differentiated thyroid cancer (DTC) as well as restaging after radioiodine therapy and long-term follow-up.

References

  1. 1.
    Ahn BC (2012) Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2(4):392–402PubMedPubMedCentralGoogle Scholar
  2. 2.
    Silberstein EB (2012) Radioiodine: the classic theranostic agent. Semin Nucl Med 42(3):164–170PubMedGoogle Scholar
  3. 3.
    Zhang J, Lazar MA (2000) The mechanism of action of thyroid hormones. Annu Rev Physiol 62:439–466PubMedGoogle Scholar
  4. 4.
    Ravera S, Reyna-Neyra A, Ferrandino G et al (2017) The sodium/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol 79:261–289PubMedPubMedCentralGoogle Scholar
  5. 5.
    Riedel C, Levy O, Carrasco N (2001) Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 276(24):21458–21463PubMedGoogle Scholar
  6. 6.
    Schmutzler C, Schmitt TL, Glaser F et al (2002) The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 189(1–2):145–155PubMedGoogle Scholar
  7. 7.
    Serrano-Nascimento C, Nicola JP, Teixeira Sda S et al (2016) Excess iodide downregulates Na(+)/I(−) symporter gene transcription through activation of PI3K/Akt pathway. Mol Cell Endocrinol 426:73–90PubMedGoogle Scholar
  8. 8.
    Vu-Phan D, Koenig RJ (2014) Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol 386(1–2):55–66PubMedGoogle Scholar
  9. 9.
    Galrao AL, Camargo RY, Friguglietti CU et al (2014) Hypermethylation of a new distal sodium/iodide symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors. J Clin Endocrinol Metab 99(6):E944–E952PubMedGoogle Scholar
  10. 10.
    Zhang Z, Liu D, Murugan AK et al (2014) Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer 21(2):161–173PubMedPubMedCentralGoogle Scholar
  11. 11.
    Riesco-Eizaguirre G, Wert-Lamas L, Perales-Paton J et al (2015) The miR-146b-3p/PAX8/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis. Cancer Res 75(19):4119–4130PubMedGoogle Scholar
  12. 12.
    Shen CT, Qiu ZL, Song HJ et al (2016) miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway. J Exp Clin Cancer Res 35(1):101PubMedPubMedCentralGoogle Scholar
  13. 13.
    O’Doherty J, Jauregui-Osoro M, Brothwood T et al (2017) (18)F-tetrafluoroborate, a PET probe for imaging sodium/iodide symporter expression: whole-body biodistribution, safety, and radiation dosimetry in thyroid cancer patients. J Nucl Med 58(10):1666–1671PubMedGoogle Scholar
  14. 14.
    Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133PubMedPubMedCentralGoogle Scholar
  15. 15.
    Lamartina L, Durante C, Filetti S et al (2015) Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab 100(5):1748–1761PubMedGoogle Scholar
  16. 16.
    Ruel E, Thomas S, Dinan M et al (2015) Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab 100(4):1529–1536PubMedPubMedCentralGoogle Scholar
  17. 17.
    Edmonds CJ, Hayes S, Kermode JC et al (1977) Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 50(599):799–807PubMedGoogle Scholar
  18. 18.
    Mazzaferri EL, Kloos RT (2002) Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87(4):1490–1498PubMedGoogle Scholar
  19. 19.
    Bianchi L, Baroli A, Lomuscio G et al (2012) Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy). Q J Nucl Med Mol Imaging 56(6):515–521PubMedGoogle Scholar
  20. 20.
    Benua RS, Cicale NR, Sonenberg M et al (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87:171–182PubMedGoogle Scholar
  21. 21.
    Maxon HR, Thomas SR, Hertzberg VS et al (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309(16):937–941PubMedGoogle Scholar
  22. 22.
    Kuker R, Sztejnberg M, Gulec S (2017) I-124 imaging and dosimetry. Mol Imaging Radionucl Ther 26(Suppl 1):66–73PubMedPubMedCentralGoogle Scholar
  23. 23.
    Chiesa C, Castellani MR, Vellani C et al (2009) Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging 53(5):546–561PubMedGoogle Scholar
  24. 24.
    Sgouros G, Kolbert KS, Sheikh A et al (2004) Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45(8):1366–1372PubMedGoogle Scholar
  25. 25.
    Flower MA, Schlesinger T, Hinton PJ et al (1989) Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma. Radiother Oncol 15(4):345–357PubMedGoogle Scholar
  26. 26.
    Dorn R, Kopp J, Vogt H et al (2003) Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 44(3):451–456PubMedGoogle Scholar
  27. 27.
    Wierts R, Brans B, Havekes B et al (2016) Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med 57(7):1027–1032PubMedGoogle Scholar
  28. 28.
    Deandreis D, Rubino C, Tala H et al (2017) Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med 58(5):717–722PubMedGoogle Scholar
  29. 29.
    Urhan M, Dadparvar S, Mavi A et al (2007) Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 34(7):1012–1017PubMedGoogle Scholar
  30. 30.
    Santhanam P, Taieb D, Solnes L et al (2017) Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 86(5):645–651Google Scholar
  31. 31.
    Haslerud T, Brauckhoff K, Reisaeter L et al (2016) F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol 57(10):1193–1200PubMedGoogle Scholar
  32. 32.
    Feine U, Lietzenmayer R, Hanke JP et al (1995) 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34(4):127–134PubMedGoogle Scholar
  33. 33.
    Leboulleux S, El Bez I, Borget I et al (2012) Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 22(8):832–838PubMedGoogle Scholar
  34. 34.
    Rosario PW, Furtado Mde S, Mineiro Filho AF et al (2012) Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. Thyroid 22(11):1165–1169PubMedGoogle Scholar
  35. 35.
    Pacini F, Capezzone M, Elisei R et al (2002) Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87(4):1499–1501PubMedGoogle Scholar
  36. 36.
    Rosario PW, Mineiro Filho AF, Lacerda RX et al (2012) The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation. Thyroid 22(2):113–116PubMedGoogle Scholar
  37. 37.
    Chudgar AV, Shah JC (2017) Pictorial review of false-positive results on radioiodine scintigrams of patients with differentiated thyroid cancer. Radiographics 37(1):298–315PubMedGoogle Scholar
  38. 38.
    Jiang X, Zeng H, Gong J et al (2015) Unusual uptake of radioiodine in a retroperitoneal bronchogenic cyst in a patient with thyroid carcinoma. Clin Nucl Med 40(5):435–436PubMedGoogle Scholar
  39. 39.
    Jiang X, Wang Q, Huang R (2015) Nasal visualization on radioiodine whole-body scintigraphy due to benign abnormality. Clin Nucl Med 40(4):340–342PubMedGoogle Scholar
  40. 40.
    Shen G, Jing X, Zhang Y et al (2017) Unusual uptake of radioiodine in a subcutaneous lipoma in a patient with differentiated thyroid cancer. Clin Nucl Med 42(1):e75–e76PubMedGoogle Scholar
  41. 41.
    Zhou H, Yan J, Huang R et al (2018) Unusual uptake of 131I in a cutaneous benign fibrous histiocytoma in a patient with thyroid cancer. Clin Nucl Med 43(1):e31–e32PubMedGoogle Scholar
  42. 42.
    Means JH, Holmes GW (1923) Further observations on the Roentgen ray treatment of toxic goiter. Arch Intern Med 31:303Google Scholar
  43. 43.
    Hertz S, Roberts A (1946) Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. JAMA 131:81–86Google Scholar
  44. 44.
    Chapman EM, Evans RD (1946) The treatment of hyperthyroidism with radioactive iodine. JAMA 131:86–91Google Scholar
  45. 45.
    Crispell KR, Parson W, Sprinkle P (1953) A simplified technique for the diagnosis of hyperthyroidism, utilizing the one-hour uptake of orally administered I131. J Clin Endocrinol Metab 13(2):221–224PubMedGoogle Scholar
  46. 46.
    Becker DV, Sawin CT (1996) Radioiodine and thyroid disease: the beginning. Semin Nucl Med 26(3):155–164PubMedGoogle Scholar
  47. 47.
    Bahn Chair RS, Burch HB, Cooper DS et al (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6):593–646PubMedGoogle Scholar
  48. 48.
    Ross DS, Burch HB, Cooper DS et al (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343–1421PubMedGoogle Scholar
  49. 49.
    Wartofsky L, Glinoer D, Solomon B et al (1991) Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1(2):129–135PubMedGoogle Scholar
  50. 50.
    Burch HB, Burman KD, Cooper DS (2012) A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 97(12):4549–4558PubMedGoogle Scholar
  51. 51.
    Meng Z, Zhang G, Sun H et al (2015) Differentiation between Graves’ disease and painless thyroiditis by diffusion-weighted imaging, thyroid iodine uptake, thyroid scintigraphy and serum parameters. Exp Ther Med 9(6):2165–2172PubMedPubMedCentralGoogle Scholar
  52. 52.
    Wang RF, Tan J, Zhang GZ et al (2010) A comparative study of influential factors correlating with early and late hypothyroidism after (131)I therapy for Graves’ disease. Chin Med J (Engl) 123(12):1528–1532Google Scholar
  53. 53.
    Zheng W, Jian T, Guizhi Z et al (2012) Analysis of (1)(3)(1)I therapy and correlation factors of Graves’ disease patients: a 4-year retrospective study. Nucl Med Commun 33(1):97–101PubMedGoogle Scholar
  54. 54.
    Rivkees SA, Sklar C, Freemark M (1998) Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 83(11):3767–3776PubMedGoogle Scholar
  55. 55.
    Boice JD Jr (2005) Radiation-induced thyroid cancer—what’s new? J Natl Cancer Inst 97(10):703–705PubMedGoogle Scholar
  56. 56.
    Bartalena L, Baldeschi L, Dickinson AJ et al (2008) Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 18(3):333–346PubMedGoogle Scholar
  57. 57.
    Davis S, Kopecky KJ, Hamilton TE et al (2004) Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the Hanford nuclear site. JAMA 292(21):2600–2613PubMedGoogle Scholar
  58. 58.
    Shore RE (1992) Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res 131(1):98–111PubMedGoogle Scholar
  59. 59.
    Read CH Jr, Tansey MJ, Menda Y (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab 89(9):4229–4233PubMedGoogle Scholar
  60. 60.
    Ron E, Doody MM, Becker DV et al (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group. JAMA 280(4):347–355PubMedGoogle Scholar
  61. 61.
    Angusti T, Codegone A, Pellerito R et al (2000) Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism. J Nucl Med 41(6):1006–1009PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Shanghai Jiao Tong University Press 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineWest China Hospital, Sichuan UniversityChengduP. R. China
  2. 2.Department of Nuclear MedicineTianjin Medical University General HospitalTianjinP. R. China

Personalised recommendations